Published in Drug Des Devel Ther on March 08, 2016
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
Rheumatoid arthritis. Lancet (2010) 9.37
Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum (2010) 3.84
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med (2012) 3.49
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis (2005) 2.48
The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol (2010) 1.95
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum (2011) 1.91
DIURNAL VARIATION IN SUPPRESSION OF ADRENAL FUNCTION BY GLUCOCORTICOIDS. J Clin Endocrinol Metab (1965) 1.90
The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum (2012) 1.85
Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum (2007) 1.78
Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol (2010) 1.78
Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis (2010) 1.78
Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum (2009) 1.76
Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis (1994) 1.73
Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol (2008) 1.49
Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis (2008) 1.47
Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum (2002) 1.36
The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford) (2006) 1.35
Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis (2014) 1.33
The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis (1997) 1.33
Rapid glucocorticoid effects on immune cells. Steroids (2002) 1.32
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis (2012) 1.31
Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin (2010) 1.31
Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms. Autoimmun Rev (2005) 1.28
Role of interleukin-6 in stress, sleep, and fatigue. Ann N Y Acad Sci (2012) 1.23
Suppression of 17-hydroxycorticosteroids in plasma and urine by single and divided doses of triamcinolone. N Engl J Med (1965) 1.16
Clinical aspects of rheumatoid arthritis. Pathophysiology (2005) 1.12
Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol (2002) 1.11
Circadian rhythms in rheumatology--a glucocorticoid perspective. Arthritis Res Ther (2014) 1.03
Single daily dose prednisone therapy. JAMA (1979) 1.01
Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol (2011) 1.00
Measurement of morning stiffness in rheumatoid arthritis clinical trials. J Clin Epidemiol (1997) 0.99
Some clinical observations on the diurnal rhythm of plasma cortisol (11-OHCS) in patients with rheumatoid arthritis treated with oral corticosteroid drugs. Curr Med Res Opin (1974) 0.97
Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther (2012) 0.96
CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence. Arthritis Res Ther (2013) 0.95
Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum (2009) 0.93
Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis (2008) 0.91
Overnight changes of immune parameters and catecholamines are associated with mood and stress. Psychosom Med (2010) 0.88
Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol (2013) 0.88
Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. J Manag Care Spec Pharm (2015) 0.87
Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis. Rheumatology (Oxford) (2014) 0.85
The current relevance and use of prednisone in rheumatoid arthritis. Expert Rev Clin Immunol (2014) 0.85
The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum (2006) 0.83
Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. RMD Open (2015) 0.81
A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. Rheumatology (Oxford) (2013) 0.81
Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition. Arthritis Res Ther (2013) 0.81
Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. J Clin Pharmacol (2013) 0.79
Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone. Scand J Rheumatol (2015) 0.79
What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis? Arthritis Care Res (Hoboken) (2015) 0.79
How much is a reduction in morning stiffness worth to patients with rheumatoid arthritis? Scand J Rheumatol Suppl (2011) 0.78
In vitro response pattern of monocytes after tmTNF reverse signaling predicts response to anti-TNF therapy in rheumatoid arthritis. J Transl Med (2015) 0.78
Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values. Clinicoecon Outcomes Res (2013) 0.78
Is the Availability of Delayed-Release Prednisone an Important Clinical Advance? Arthritis Care Res (Hoboken) (2016) 0.76
The 2010 ACR/EULAR classification criteria for rheumatoid arthritis in the Heinola inception cohort--diagnoses confirmed by long-term follow-up. Clin Rheumatol (2011) 0.76